Ibrahim Halil Sahin, MD

Gastrointestinal Oncology

Medical Oncologist

Published Articles (4)

Gastrointestinal Cancer Updates From the Best of GI Oncology 2026

August 20, 2026

Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.

Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer

June 24, 2026

For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.

The Immunotherapy Landscape in Colorectal Cancer: Where We Stand and Where We're Headed

May 13, 2026

Expert commentary on the evolving role of immunotherapy in colorectal cancer, including MSI-H breakthroughs, MSS challenges, biomarker-driven treatment, and emerging clinical trial strategies.

Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside

January 27, 2026

Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.